Last reviewed · How we verify

Triamcinolone 0.1%

Johns Hopkins University · FDA-approved active Small molecule Under review Quality 0/100

Triamcinolone 0.1% is a Corticosteroid Small molecule drug developed by Johns Hopkins University. It is currently FDA-approved for Inflammatory and pruritic dermatoses (topical), Eczema, psoriasis, and other corticosteroid-responsive skin conditions. Also known as: Triamcinolone 0.1% ointment.

Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Triamcinolone 0.1% is a glucocorticoid receptor agonist, classified as a small molecule. It has been studied for various conditions, including inflammatory punctal stenosis, keloid, and cataract, often in combination with punctal dilation.

At a glance

Generic nameTriamcinolone 0.1%
Also known asTriamcinolone 0.1% ointment
SponsorJohns Hopkins University
Drug classCorticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology, Immunology
PhaseFDA-approved

Mechanism of action

Triamcinolone exerts its anti-inflammatory effects by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. The 0.1% formulation is typically used for topical application to reduce localized inflammation and immune-mediated skin conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Triamcinolone 0.1%

What is Triamcinolone 0.1%?

Triamcinolone 0.1% is a Corticosteroid drug developed by Johns Hopkins University, indicated for Inflammatory and pruritic dermatoses (topical), Eczema, psoriasis, and other corticosteroid-responsive skin conditions.

How does Triamcinolone 0.1% work?

Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

What is Triamcinolone 0.1% used for?

Triamcinolone 0.1% is indicated for Inflammatory and pruritic dermatoses (topical), Eczema, psoriasis, and other corticosteroid-responsive skin conditions.

Who makes Triamcinolone 0.1%?

Triamcinolone 0.1% is developed and marketed by Johns Hopkins University (see full Johns Hopkins University pipeline at /company/johns-hopkins-university).

Is Triamcinolone 0.1% also known as anything else?

Triamcinolone 0.1% is also known as Triamcinolone 0.1% ointment.

What drug class is Triamcinolone 0.1% in?

Triamcinolone 0.1% belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is Triamcinolone 0.1% in?

Triamcinolone 0.1% is FDA-approved (marketed).

What are the side effects of Triamcinolone 0.1%?

Common side effects of Triamcinolone 0.1% include Skin atrophy, Striae, Telangiectasia, Local irritation or burning, Systemic absorption (with prolonged use on large areas).

What does Triamcinolone 0.1% target?

Triamcinolone 0.1% targets Glucocorticoid receptor and is a Corticosteroid.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing